Further investigations on various ex vivo stimulations followed by HDCyto analyses in monitoring patient's immune status and their response to immunomodulatory treatments such as IFN-γ, immune checkpoint inhibitors, tocilizumab and steroids, may allow clinician to tailor sepsis treatments. This evidence concerns the gene IFNG and Sepsis.